<DOC>
	<DOCNO>NCT00740532</DOCNO>
	<brief_summary>Aim study assess impact response Herceptin-based therapy patient advance breast cancer . Tumor specimens primary breast cancer analized several biological factor potentially involved Herceptin sensitivity . Tests perform include : FISH analysis EGFR , HER-2 , HER-3 , C-MYC , PTEN , MET , IGFR-1 . Immunofluorecence P95HER2 . Mutation analyse EGFR , HER-2 , MET , C-MYC , PTEN , KRAS , PIK3CA , IGFR-1 . Immunohistochemistry biomarkers .</brief_summary>
	<brief_title>Molecular Features Predicting Response/Resistance Trastuzumab Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Hystological diagnosis breast cancer Availability tumor tissue Availability ass response Trastuzumab accord RECIST criterion Availability clinical data Unavailability tumor tissue Impossibility ass response Trastuzumab accord RECIST criterion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>EGFR , HER-2 , HER-3 , MET , KRAS</keyword>
</DOC>